Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
N Engl J Med. 2015 Apr 16;372(16):1489-99.
11
May
May
2015
10 years ago
Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy.
To assess safety and efficacy of alirocumab, new randomized trial was conducted, involving 2,341 patients at high risk for CV events, receiving treatment with statins at the maximum tolerated dose. Patients were randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo every 2 weeks for 78 weeks.
Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab.
Go to NCBI abstract
To assess safety and efficacy of alirocumab, new randomized trial was conducted, involving 2,341 patients at high risk for CV events, receiving treatment with statins at the maximum tolerated dose. Patients were randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo every 2 weeks for 78 weeks.
Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab.
Go to NCBI abstract